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Abstract
Background: We investigated time trends in age, gender, 
growth hormone (GH) dose and height standard deviation 
score (SDS) in children with GH deficiency (GHD), born 
small for gestational age (SGA) or with Turner syndrome 
(TS) starting GH treatment.
Methods: Data were obtained from children enrolled in 
the NordiNet® International Outcome Study (IOS) between 
2006 and 2015 in the Czech Republic, France, Germany, 
Serbia and Montenegro (all indications), and Switzer-
land and the UK (GHD only). Trends were analyzed by 
linear regression. Patients were divided by age into early-, 
medium- or late-start groups in three different time periods.
Results: Approximately one-third of children starting 
treatment for GHD were girls, with no apparent increase in 
proportion over time. The mean baseline age for starting 
treatment decreased significantly (p < 0.001) for both GHD 
and SGA in the Czech Republic and Germany. In the other 
countries studied, over 40% of children started treatment 
for GHD and SGA late (girls >10, boys >11 years) between 
2013 and 2015. The mean baseline GH doses were largely 
within recommended ranges for GHD and SGA, but below 
the lowest recommended starting dose for TS in almost 
every year since 2011 except in France.
Conclusions: Approximately one-third of children starting 
treatment for GHD were girls. Between 2013 and 2015, more 
than 40% of children started treatment for GHD and SGA 
late except in Germany and the Czech Republic. TS patients 
received below-recommended doses. These results high-
light the need for earlier identification of short stature in 
children, particularly girls, and for dose optimization in TS.
Keywords: growth hormone; growth hormone deficiency; 
NordiNet® International Outcome Study; small for gesta-
tional age; Turner syndrome.
Introduction
A number of studies have reported on factors associated 
with response to growth hormone (GH) therapy for different 
indications. In GH deficiency (GHD), age at GH treatment 
start and height deficit at baseline are inversely associated, 
whereas GH dose is positively associated, with the response 
[1–3]. Age at treatment start and GH dose were also shown 
to be similarly associated with growth response in children 
born small for gestational age (SGA) without postnatal 
catch-up growth [1, 4, 5] and in Turner syndrome (TS) [1, 6, 
7]. In light of this evidence, it is of interest to investigate real-
life baseline characteristics of children starting treatment 
with GH, as recorded in databases such as the NordiNet® 
International Outcome Study (IOS) and the Pfizer Interna-
tional Growth Study (KIGS®), and to examine whether clini-
cal practice has changed over time.
The objectives of the current study were to analyze 
data from NordiNet® IOS to evaluate trends over 10 years 
(2006–2015) in the age and height standard deviation 
score (SDS) at which children start GH treatment for GHD, 
SGA and TS; to investigate whether adequate baseline 
doses of GH were prescribed over this period; and to iden-
tify the proportion of girls treated among patients with 
GHD and born SGA. As such, the current analysis aims to 
support and provide additional evidence on aspects dif-
ferent to those reported in two recent studies [8, 9].
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Materials and methods
NordiNet® IOS (ClinicalTrials.gov identifier: NCT00960128) is a non-
interventional, multicenter study evaluating the long-term effective-
ness and safety of Norditropin® (somatropin; Novo Nordisk A/S, 
Copenhagen, Denmark) as prescribed by the treating physicians in 
the real-life clinical setting. NordiNet® IOS was launched in 2006 and 
data are collected from 23 countries [10].
Children (aged <18  years) with isolated GHD, born SGA or 
with TS enrolled in NordiNet® IOS who started treatment with GH 
between 1 January 2006 and 31 December 2015  were included in 
this analysis. Clinical diagnoses were based on the judgment of the 
treating physician. For GHD, we analyzed only patients with iso-
lated GHD; those with additional pituitary hormone deficiencies 
were excluded.
In order to draw meaningful conclusions, only countries with a 
minimum number of enrolled eligible patients were included in the 
analyses. Following a preliminary feasibility analysis, this was set at 
100 patients for GHD and those born SGA, and 50 patients for TS. 
For GHD, six countries/country groups met this criterion: the Czech 
Republic, France, Germany, Serbia and Montenegro, Switzerland 
and the UK. Serbia and Montenegro were grouped together because 
data from both countries are collected through the same enrolment 
flow. For SGA and TS, the Czech Republic, France, Germany, and Ser-
bia and Montenegro met the criterion.
NordiNet® IOS is conducted in accordance with the Declaration 
of Helsinki and Good Pharmacoepidemiology Practice guidelines 
[11]. All patients, or their guardians in the case of minors, provide 
written informed consent for data collection, and all data collected 
within NordiNet® IOS are anonymized. Centers are included in 
 NordiNet® IOS only after approval of the Local Ethics Committee or 
Institutional Review Board at individual center level, in accordance 
with country-specific rules.
Descriptive statistics were applied to age at treatment start, base-
line dose of GH, and baseline height SDS, and are presented as mean 
(standard deviation, SD). Gender distribution in patients with GHD 
and those born SGA was determined for each year from 2006 to 2015 
inclusive. Time trends in age at treatment start, baseline dose of GH, 
and baseline height SDS within each country were analyzed for each 
parameter by linear regression, including calendar year as explana-
tory variable in the model. Regression plots were used to illustrate 
data trends. The distribution of patients by age group at treatment 
start (early: girls aged <8 years, boys aged <9 years; medium: girls 
aged 8–10 years, boys aged 9–11 years; and late: girls aged >10 years, 
boys aged >11  years) in three time periods (2006–2009, 2010–2012 
and 2013–2015) was also determined and reported descriptively.
Statistical analysis was performed using SAS v9.4 (SAS Insti-
tute Inc., Cary, NC, USA). Height SDS was calculated using relevant 
national references [12–16], or, for Serbia and Montenegro, the Cent-
ers for Disease Control and Prevention reference [17].
Results
This analysis included 3974 patients with GHD, 1926 born 
SGA without spontaneous catch-up growth and 428 with 
TS (Table 1A–C). Ta
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GHD
For all years combined, in each country, approximately 
one-third of included patients with GHD were female, 
except in Switzerland, where only 24.7% of patients were 
female (Table 1A). No clear pattern of change was observed 
in any country over time.
The mean age at treatment start by year is shown in 
Table 2A. For all years combined, the mean (SD) age at treat-
ment start ranged from 8.2 (4.1) years (Czech Republic) to 
11.2 (3.5) years (Serbia and Montenegro). From 2006 to 2015 
the observed mean age at treatment start decreased from 
11.4 (3.6) to 7.3 (3.6) years in the Czech Republic, and from 
10.0 (3.9) to 7.7 (3.7) years in Germany (Table 2A); the trend 
of a decrease in age over time was statistically significant 
for both countries (p < 0.001) (Supplemental Figure  1A). 
Consequently, the proportions of children starting treat-
ment early increased and the proportion starting treatment 
late decreased over time in these two countries (Figure 1). 
In the remaining countries, the mean age at treatment start 
did not show a clear trend (Table 2A, Supplemental Figure 
1A), although the proportion of patients starting treatment 
late appeared to increase over time in France (Figure 1). In 
France, Serbia and Montenegro, Switzerland, and the UK, 
Table 2: Age at treatment start in years, shown as mean (SD) for patients with GHD, short patients born SGA and patients with TS.
GH start year   Czech Republic  France  Germany  Serbia and 
Montenegro
  Switzerland  UK
(A) Patients with GHD
2006   11.4 (3.6)  9.9 (3.8)  10.0 (3.9)  10.9 (3.5)  9.1 (3.5)  9.6 (3.6)
2007   9.2 (4.1)  8.7 (4.5)  9.5 (4.1)  11.2 (3.6)  11.0 (3.1)  8.6 (5.6)
2008   10.6 (3.7)  9.2 (4.4)  9.3 (3.8)  11.1 (3.5)  7.6 (2.7)  9.1 (5.0)
2009   10.0 (4.5)  9.0 (4.1)  9.5 (3.6)  11.6 (4.2)  9.9 (3.8)  11.5 (3.4)
2010   8.8 (3.9)  9.6 (4.3)  8.5 (3.9)  10.2 (3.3)  9.7 (4.1)  10.0 (4.9)
2011   7.3 (4.0)  9.3 (4.4)  8.2 (3.8)  10.7 (3.5)  9.6 (3.3)  9.2 (5.1)
2012   7.2 (3.9)  9.5 (4.5)  8.5 (4.1)  11.0 (3.3)  10.3 (3.7)  10.7 (4.2)
2013   7.1 (4.0)  10.1 (4.1)  8.3 (4.1)  11.7 (3.4)  10.1 (4.0)  9.7 (3.9)
2014   7.0 (3.9)  10.6 (3.6)  8.6 (3.7)  11.1 (3.7)  9.5 (2.9)  9.5 (3.8)
2015   7.3 (3.6)  9.5 (4.0)  7.7 (3.7)  11.6 (3.1)  10.5 (3.6)  11.6 (4.4)
All   8.2 (4.1)  9.6 (4.2)  9.0 (3.9)  11.2 (3.5)  9.7 (3.6)  9.7 (4.5)
(C) Patients with TS
2006   7.4 (6.1)  6.7 (3.9)  7.9 (3.7)  10.6 (4.1)
2007   6.7 (4.1)  9.3 (3.3)  10.2 (4.0)  6.5 (3.0)
2008   13.5 (2.0)  8.5 (3.5)  8.8 (2.8)  12.1 (1.9)
2009   8.9 (3.4)  7.5 (3.7)  8.0 (4.6)  12.0 (2.2)
2010   9.0 (3.0)  8.6 (3.8)  6.7 (4.0)  6.2 (3.9)
2011   11.7 (2.2)  8.4 (3.2)  6.2 (3.1)  14.8 (2.3)
2012   7.6 (4.6)  7.7 (3.5)  8.7 (3.9)  8.6 (2.2)
2013   7.8 (3.8)  8.5 (4.1)  7.6 (3.3)  8.8 (3.2)
2014   8.8 (3.0)  7.8 (3.7)  10.9 (3.8)  8.6 (2.3)
2015   9.1 (3.4)  9.9 (4.3)  7.0 (2.5)  9.6 (4.6)
All   8.7 (3.7)  8.3 (3.7)  8.0 (3.8)  9.6 (3.7)
aNot applicable (n = 1). GHD, growth hormone deficiency; SGA, small for gestational age; SD, standard deviation; TS, Turner syndrome.
GH start year   Czech Republic  France  Germany  Serbia and 
Montenegro
(B) Short patients born SGA
2006   9.3 (3.6)  7.5 (3.2)  7.5 (3.2)  7.1 (2.6)
2007   8.4 (3.2)  8.1 (4.0)  7.5 (3.1)  8.6 (a)
2008   6.5 (2.7)  8.1 (3.2)  8.3 (2.8)  7.6 (3.6)
2009   8.3 (3.9)  8.9 (3.3)  7.6 (2.8)  11.1 (4.0)
2010   6.8 (3.5)  8.5 (3.6)  7.4 (3.0)  8.5 (3.5)
2011   5.7 (3.0)  8.5 (3.8)  6.9 (3.1)  8.7 (4.2)
2012   6.5 (2.7)  9.0 (3.9)  6.2 (2.3)  8.8 (4.2)
2013   5.9 (2.8)  8.4 (3.5)  6.5 (2.5)  9.4 (4.3)
2014   7.4 (3.0)  8.6 (3.8)  6.6 (2.4)  9.1 (3.7)
2015   5.9 (1.7)  9.5 (3.7)  6.1 (2.4)  9.0 (3.5)
All   6.9 (3.2)  8.5 (3.6)  7.3 (2.9)  9.0 (3.8)
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more than 40% of children started treatment late between 
2013 and 2015.
The mean baseline doses in the different countries 
over the 10-year period (Table 3A) were mostly within 
the range of 25–35 μg/kg/day, as recommended in the 
Summary of Product Characteristics [18] and  generally 
recommended in Europe. The mean (SD) baseline dose of 
GH for all years was higher in France (35.5 [7.3] μg/kg/day) 
and Switzerland (33.6 [8.6] μg/kg/day) than in the other 
countries analyzed (where the mean for all years ranged 
from 27.8–30.5 μg/kg/day; Table 3A). Although GH dose 
decreased statistically significantly over time in Germany 
(p = 0.038) (Supplemental Figure 1B), the decrease in 
actual mean dose was small – from 29.4 (7.4) to 27.8 (5.2) 
μg/kg/day – and, thus, of limited clinical relevance.
The mean height SDS values at baseline were below 
−2 SDS in all years in all countries, with a few excep-
tions (full data not shown). The mean (SD) height SDS 
values at baseline for the 10-year period overall ranged 
from −2.2 (1.5) (UK) to −2.6 (1.0) (Czech Republic). No 
statistically significant trends were observed over time 
except in Serbia and Montenegro, where in later years, 
Figure 1: Distribution of patients with GHD by GH treatment start period (2006–2009, 2010–2012 or 2013–2015) and age group.
Age groups were as follows: early: girls aged <8 years, boys aged <9 years; medium: girls aged 8–10 years, boys aged 9–11 years; and 
late: girls aged >10 years, boys aged >11 years. Distribution is shown as percentage of patients in each age group in the relevant period. 
GH, growth hormone; GHD, growth hormone deficiency.
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Table 3: GH dose at treatment start in μg/kg/day, shown as mean (SD) for patients with GHD, short patients born SGA and patients with TS.
GH start year   Czech Republic  France  Germany  Serbia and 
Montenegro
  Switzerland  UK
(A) Patients with GHD
2006   33.0 (9.7)  35.3 (6.0)  29.4 (7.4)  30.6 (6.3)  32.3 (5.7)  30.3 (3.2)
2007   28.0 (7.1)  35.8 (8.3)  28.4 (7.1)  29.5 (4.7)  33.8 (10.0)  30.1 (6.0)
2008   29.5 (5.3)  36.0 (8.0)  27.5 (5.4)  29.4 (6.5)  36.3 (8.1)  29.6 (7.3)
2009   30.5 (5.7)  36.6 (8.4)  27.7 (6.0)  31.5 (6.0)  31.4 (9.5)  27.5 (5.1)
2010   30.0 (6.3)  35.9 (9.6)  27.4 (6.9)  30.5 (3.8)  33.3 (9.2)  30.2 (6.0)
2011   30.7 (5.3)  34.7 (6.8)  27.4 (4.6)  29.9 (4.7)  33.1 (8.1)  28.3 (5.5)
2012   28.0 (4.9)  35.3 (5.7)  27.3 (6.0)  32.2 (6.9)  35.2 (9.2)  28.5 (3.7)
2013   29.8 (5.0)  34.3 (5.2)  27.9 (5.5)  31.0 (6.4)  33.6 (7.9)  26.0 (5.0)
2014   30.8 (4.7)  36.3 (6.6)  26.5 (3.4)  29.6 (5.6)  33.7 (9.0)  27.0 (4.3)
2015   29.5 (4.9)  34.8 (5.4)  27.8 (5.2)  30.0 (4.3)  31.5 (5.9)  26.5 (4.2)
All   30.0 (5.7)  35.5 (7.3)  27.8 (6.1)  30.5 (5.7)  33.6 (8.6)  28.3 (5.5)
Year   Czech Republic  France  Germany  Serbia and 
Montenegro
(B) Short patients born SGA
2006   38.5 (8.9)  44.7 (10.6)  34.6 (4.4)  65.4 (1.3)
2007   34.8 (6.7)  43.7 (11.8)  33.6 (5.3)  50.0 (a)
2008   33.4 (8.1)  41.6 (10.9)  33.0 (6.1)  40.3 (10.0)
2009   34.2 (4.8)  43.4 (10.5)  32.2 (6.3)  33.9 (9.7)
2010   39.2 (7.7)  44.3 (9.3)  34.2 (5.3)  32.9 (7.9)
2011   33.0 (5.6)  37.6 (6.5)  32.5 (6.8)  32.6 (7.7)
2012   36.0 (5.5)  40.2 (10.1)  30.0 (6.9)  32.7 (11.1)
2013   34.9 (3.2)  37.4 (6.6)  32.9 (5.1)  32.9 (7.6)
2014   34.1 (3.1)  41.0 (10.4)  31.4 (4.5)  30.7 (7.7)
2015   34.2 (2.8)  40.9 (9.1)  32.2 (4.5)  31.4 (5.6)
All   35.1 (6.1)  41.5 (9.9)  33.0 (5.7)  32.6 (8.6)
(C) Patients with TS
2006   45.6 (3.7)  48.1 (8.9)  40.5 (10.7)  47.6 (7.3)
2007   49.1 (4.3)  49.2 (4.1)  41.5 (8.6)  44.1 (9.4)
2008   47.9 (4.9)  49.0 (4.0)  43.8 (10.2)  44.0 (13.7)
2009   43.5 (4.3)  47.5 (9.6)  42.6 (14.2)  45.4 (4.6)
2010   44.0 (7.4)  48.7 (10.7)  43.2 (9.5)  45.2 (5.0)
2011   45.2 (2.1)  45.7 (9.0)  38.5 (12.8)  44.5 (1.0)
2012   42.4 (6.7)  43.4 (10.7)  39.5 (10.7)  42.7 (6.2)
2013   42.3 (6.3)  45.5 (10.1)  37.3 (7.2)  43.5 (6.2)
2014   41.6 (4.2)  40.2 (9.8)  31.8 (10.1)  43.6 (6.1)
2015   43.7 (8.0)  45.6 (10.0)  36.5 (11.2)  39.8 (10.1)
All   44.1 (5.9)  46.3 (9.3)  40.0 (11.0)  44.4 (7.9)
aNot applicable (n = 1). GHD, growth hormone deficiency; SGA, small for gestational age; SD, standard deviation; TS, Turner syndrome.
patients were less growth retarded at diagnosis (Sup-
plemental Figure 1C).
SGA
Proportions of female and male patients reported in each 
country fluctuated over time, but remained largely stable 
and were approximately equal (Table 1B).
The mean (SD) age at treatment start in patients 
born SGA for all years combined ranged from 6.9 (3.2) 
years (Czech Republic) to 9.0 (3.8) years (Serbia and 
Montenegro; Table 2B). From 2006 to 2015, the mean age 
decreased from 9.3 (3.6) to 5.9 (1.7) years in the Czech 
Republic (p = 0.032 for trend over time) and from 7.5 
(3.2) to 6.1 (2.4) years in Germany (p = 0.003) (Table 2B 
and Supplemental Figure 2A). Over time, greater pro-
portions of children started treatment early and lower 
proportions started treatment late in these two countries 
(Figure 2). Conversely, in France, mean age at treatment 
start increased from 7.5 (3.2) years in 2006 to 9.5 (3.7) 
years in 2015 – a statistically significant increase over 
time (p = 0.003), reflected in an increasing proportion of 
patients in the late treatment start group (Table 2B and 
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Figure 2). In both France and Serbia and Montenegro, 
over 40% of patients started treatment late between 
2013 and 2015 (Figure 2).
The mean (SD) baseline dose of GH calculated for 
the 10-year period ranged from 32.6 (8.6) μg/kg/day 
(Serbia and Montenegro) to 41.5 (9.9) μg/kg/day (France; 
Table  3B). The baseline dose was generally higher in 
France than in the other countries. From 2006 to 2015, the 
actual mean dose decreased from 34.6 (4.4) to 32.2 (4.5) μg/
kg/day in Germany (p = 0.046 for trend over time) (Table 
3B and Supplemental Figure 2B). Similarly in France, the 
actual mean (SD) dose decreased from 44.7 (10.6) to 40.9 
(9.1) μg/kg/day (p = 0.045). The mean dose decreased over 
time in Serbia and Montenegro, but patient numbers were 
low from 2006 to 2010 (Table 1B).
Children born SGA were very short at baseline, with 
mean height SDS values well below –2.5; this was observed 
over the whole period (full data not shown). The mean 
(SD) baseline height SDS values were between −2.6 (0.8) 
and −3.2 (0.9) in all years in all countries except Serbia and 
Montenegro, where they were generally between −2.0 (0.9) 
and −2.9 (1.4). In Germany between 2006 and 2015, a trend 
for shorter stature at diagnosis was observed (p = 0.003) 
(Supplemental Figure 2C). Conversely, in Serbia and Mon-
tenegro, children initiating GH treatment exhibited less 
growth retardation over time; again, patient numbers 
were very low from 2006 to 2010.
Turner syndrome
The mean (SD) age at baseline across all years for patients 
with TS was as follows: Czech Republic, 8.7 (3.7) years; 
France, 8.3 (3.7) years; Germany, 8.0 (3.8) years; and 
Serbia and Montenegro, 9.6 (3.7) years (Table 2C). No sta-
tistically significant trends in age at treatment start were 
observed (Supplemental Figure 3A). The distribution of 
patients by age at treatment start is shown in Figure 3; 
Figure 2: Distribution of short children born SGA by GH treatment start period (2006–2009, 2010–2012 or 2013–2015) and age group.
Age groups were as follows: early: girls aged <8 years, boys aged <9 years; medium: girls aged 8–10 years, boys aged 9–11 years; and 
late: girls aged >10 years, boys aged >11 years. Distribution is shown as percentage of patients in each age group in the relevant period. 
GH, growth hormone; SGA, small for gestational age.
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patient numbers were too low to allow conclusions on pat-
terns over time.
The mean (SD) baseline GH dose for all years 
ranged  from 40.0 (11.0) μg/kg/day in Germany to 
46.3  (9.3) μg/kg/day in France (Table 3C). Generally, the 
lowest mean doses were reported in Germany, ranging 
from 31.8  (10.1) to 43.8 (10.2) μg/kg/day, and the highest 
in France, ranging from 40.2 (9.8) to 49.2 (4.1) μg/kg/
day. From 2006 to 2015, the actual mean dose decreased 
from 45.6 (3.7) to 43.7 (8.0) μg/kg/day in the Czech Repub-
lic (p = 0.014 for trend over time), from 48.1 (8.9) to 45.6 
(10.0) μg/kg/day in France (p = 0.016), and from 40.5 (10.7) 
to 36.5 (11.2) μg/kg/day in Germany (p = 0.013) (Table 3C 
and Supplemental Figure 3B). These decreases were sta-
tistically significant and the mean doses were below the 
lowest recommended starting dose (45 μg/kg/day [18]) in 
all years in Germany, and in all years from 2012 to 2015 
inclusive in the other countries, except for France.
The 10-year overall mean (SD) baseline height SDS 
values ranged from −2.3 (0.9) in France to −2.7 (1.0) in 
Serbia and Montenegro (full data not shown). Over time, 
height SDS decreased statistically significantly in France 
(p = 0.033), i.e. girls were becoming shorter at diagnosis 
(Supplemental Figure 3C).
Discussion
Analyses of data from NordiNet® IOS were undertaken to 
shed light on trends over time and differences in clinical 
practice between countries, with the aim of helping to 
optimize treatment, if clinical practice seems to diverge 
from treatment recommendations. The current analysis 
adds to the knowledge gained from a recent study of the 
KIGS® data [9] by examining different patient populations, 
and also supplements a recent report based on NordiNet® 
IOS [8] by analyzing the changes in baseline characteris-
tics over time and by reporting proportions of patients by 
gender (GHD and SGA).
In the present study, girls generally made up a smaller 
proportion of patients treated for GHD than boys. The 
under-representation of girls treated for GHD has been 
reported previously [19, 20] and was also noted by Ranke 
and colleagues [9] for idiopathic GHD in their analysis 
of KIGS® data. This apparent gender bias may be due to 
under-referral of girls for short stature, or to over-referral 
of boys without organic causes of short stature [20]; alter-
natively, several studies have suggested that biological 
differences between the sexes may also contribute to the 
different number of boys and girls treated for short stature 
Figure 3: Distribution of patients with TS by GH treatment start period (2006–2009, 2010–2012 or 2013–2015) and age group.
Age groups were as follows: early: girls aged <8 years, boys aged <9 years; medium: girls aged 8–10 years, boys aged 9–11 years; and 
late: girls aged >10 years, boys aged >11 years. Distribution is shown as percentage of patients in each age group in the relevant period. 
GH, growth hormone; TS, Turner syndrome.
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 29.01.19 14:16
Polak et al.: GH therapy baseline data over 10 years from NordiNet® IOS      529
[21–23]. Nevertheless, these findings emphasize the need 
for accurate growth monitoring during the healthcare 
maintenance of all children, particularly girls, to ensure 
appropriate referral and treatment.
An earlier age at treatment start has been shown to be 
associated with a better growth response among children 
with GHD [2], born SGA [4, 5] or with TS [6, 7]. A report 
from the ANSWER study showed significantly greater 
changes in height SDS during both years 1 and 2 of treat-
ment of GHD for girls younger than 10  years compared 
with those 10  years or older and for boys younger than 
11  years compared with those 11  years or older [24]. Sig-
nificant differences between the two age groups were also 
shown for boys born SGA and for girls with TS [24]. Fur-
thermore, a recent study demonstrated that early initia-
tion of GH treatment in children with isolated GHD (girls 
aged <8 years, boys aged <9 years) improves their chance 
of achieving their genetic height potential [25]. The associ-
ation between early treatment start and increased attain-
ment of near-adult height and genetic potential in patients 
with GHD has also been shown in a study conducted in 
Sweden [3] and in studies confirming the importance of 
starting treatment before pubertal onset [26, 27].
In the present analysis, observed decreases over 
time in mean age at treatment start for GHD in the Czech 
Republic and Germany are relevant, as they mean that 
more children were prepubertal or in the early age group 
at treatment start. These changes were probably due to 
earlier detection of GHD, and in some cases to more precise 
diagnosis. However, large proportions of children with 
GHD still started treatment late in all countries between 
2013 and 2015. Early detection of abnormal growth and 
referral to a pediatric endocrinologist, so that the underly-
ing cause(s) can be identified, are critical for appropriate 
treatment. It is generally considered preferable that treat-
ment with GH should start as soon as GHD has been diag-
nosed [28]. Aside from the evidence that age at treatment 
start is inversely associated with the response to therapy, 
starting GH replacement early also allows a longer dura-
tion of treatment and therefore more time for catch-up 
growth before children reach puberty, with the potential 
for better outcomes [29].
GH is indicated for use in short children born SGA 
who have failed to show catch-up growth by 4 years of 
age or later. The mean age at treatment start was well 
above 4 years in all the countries studied. The mean age 
decreased over time in the Czech Republic and Germany, 
but increased in France.
For TS, any interpretation of trends must be made 
with caution, as patient numbers were low. The mean age 
at treatment start ranged from 8.0 to 9.6  years between 
countries, with no clear patterns of change over time. Cate-
gorization by age group suggested large proportions of girls 
start treatment only after the age of 10 years. As with GHD 
and SGA, greater improvements in height gain have been 
associated with earlier treatment [7, 24, 30]. In line with 
earlier recommendations [31], many physicians start GH 
when the height of a girl who has been diagnosed with TS 
drops below the fifth percentile (approximately −1.645 SDS) 
on the growth chart, and in practice this has translated to 
an average starting age of 9 years [32, 33]. Recent guidelines 
from the International Turner Syndrome Consensus Group 
recommend initiating GH at around 4–6 years of age in chil-
dren who have evidence of growth failure in the absence of 
other treatable causes, or who are already short or have a 
strong likelihood of short stature [34].
In models developed to identify the response to GH 
therapy, GH dose is a predictive variable for increase in 
height velocity in patients with GHD [2], born SGA [5] or 
with TS [6, 7]. The mean baseline doses for GHD in the dif-
ferent countries over the 10-year period were within the 
range of 25–35 μg/kg/day recommended in the Summary of 
Product Characteristics [18] and generally recommended 
in Europe. The observed slight decrease in dose over time 
in Germany might have been related to the younger age of 
the children at treatment start.
For patients born SGA, the baseline dose decreased 
over time in France and Germany, but remained close to 
or within the dose range recommended in an international 
consensus statement (35–70 μg/kg/day) [35]. In France, 
where patients born SGA were older at treatment start, 
the average GH doses were at the higher end of the label 
range. This may reflect differences between France and 
the other countries in the approved GH dose (upper dose, 
50 μg/kg/day). The observed mean starting doses in France 
were smaller from 2011 onwards compared with preced-
ing years. In 2010, the French Health Agency (AFSSAPS) 
issued an alert concerning GH treatment in childhood, 
referring to preliminary results from the French cohort of 
the European Union Safety and Appropriateness of GH 
treatments in Europe (EU SAGhE) study [36, 37]. However, 
a later position statement from an international GH safety 
workshop  concluded that there was good available evi-
dence in support of the use of recommended doses of GH in 
approved indications [38].
For patients with TS, the recommended dose range 
according to the Norditropin® Summary of Product Char-
acteristics is between 45 and 67 μg/kg/day [18]. The recent 
guidelines recommend a starting dose of between 45 and 
50 μg/kg/day in most cases, increasing to 68 μg/kg/day 
if needed [34]; in particular, higher doses may be con-
sidered in girls with a poor adult height prognosis. In a 
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study based on a database of all children receiving GH in 
Australia, Hughes and colleagues [39] concluded that the 
GH dose in the first year of treatment is a critical factor in 
determining the overall change in height SDS over the first 
3 years of treatment. Importantly, a dose increment after 
the first year did not reverse the normal decline in the 
growth response. These authors suggested an age–dose 
interaction in patients with TS, highlighting the impor-
tance of both starting treatment at a young age and initiat-
ing treatment at a high dose. Furthermore, a study based 
on data from both NordiNet® IOS and ANSWER concluded 
that increase in height SDS was higher for patients with 
younger baseline age and higher GH dose, and that these 
findings support safe treatment optimization, including 
individualized GH dose titration consistent with approved 
product labels [40].
In the current analysis, the mean baseline doses for 
TS were low and were below 45 μg/kg/day in some years 
in all countries studied. The mean baseline dose also 
decreased significantly over time in the Czech Republic, 
France and Germany, decreasing in some cases to values 
even further below the recommended dose range. These 
low doses may reflect local conditions, such as an empha-
sis on safety. However, the evidence cited above indicates 
that starting below the recommended dosing range will 
not provide optimal results in the majority of patients.
The changes in height SDS values do not allow any 
conclusions to be drawn. The use of national references 
[12–17] to calculate the height SDS values may have con-
tributed to the observed differences between countries, 
but was considered more appropriate than using a single 
reference. This conclusion was based on a recent study 
[41] that showed using updated national growth refer-
ences may identify growth disorders with greater sensi-
tivity than using international standards such as those 
produced by the World Health Organization [42, 43]. A lim-
itation of our approach is the fact that some national refer-
ences were more recent than others. However, our focus 
was on changes in height SDS over time in each country 
rather than differences in absolute values.
Other limitations of the present analyses are that 
only patients receiving treatment with Norditropin® and 
enrolled in NordiNet® IOS by the treating clinicians were 
included, which may represent a selection bias; that the 
comparisons across countries made here have not taken 
into account the variations in diagnostic criteria and the 
methods used, except where these are specifically dis-
cussed; that the mean values by country may also dis-
guise different practices at treatment centers within each 
country; and that numbers in some countries were small 
for some indications and years.
Strengths of the study include the data validation 
at entry, as information is captured via a Good Clini-
cal Practice-certified electronic platform, and the large 
number of enrolled patients in the GHD sub-cohort. This 
overview of trends over 10 years in real-life prescribing, 
without the limitations or time constraints associated 
with the short-term setting of a clinical trial, provides 
real-world evidence of the current and evolving practice 
of GH use.
Conclusions
This analysis of patients from six (GHD) or four (SGA, TS) 
countries showed trends that may indicate earlier diag-
nosis of and referral for these conditions from 2006 to 
2015 in some countries. However, some aspects of real-
life treatment practices still require increased awareness. 
For GHD, in four countries more than 40% of patients 
still started treatment late (i.e. aged >10 [girls] or 11 years 
[boys]) between 2013 and 2015, which may compromise 
their chances of achieving their genetic height potential. 
In general, more boys than girls with GHD were treated. 
Furthermore, the majority of patients with TS received GH 
doses below the lowest recommended dose. These results 
highlight the need for improved referral for treatment of 
children with short stature, and for dose optimization in 
patients with TS.
Acknowledgments: The authors thank all the physi-
cians who contributed patient data to NordiNet® IOS. 
The authors would also like to thank Anita Chudecka 
(Novo Nordisk Health Care AG) for her statistical support. 
Medical writing and submission support were provided 
by Grace Townshend, MSc, and Germanicus Hansa- 
Wilkinson, MSc, of Watermeadow Medical, funded by 
Novo Nordisk Health Care AG.
Author contributions: BTP oversaw the research design 
and acquisition of data. BTP and GP oversaw the analysis 
of the data. All authors confirm that they made a substan-
tial contribution to research design, or the acquisition, 
analysis or interpretation of data; have revised the man-
uscript critically; have approved the final version; and 
accept responsibility for the entire content of the manu-
script. All the authors have accepted responsibility for the 
entire content of this submitted manuscript and approved 
submission.
Research funding: This study was sponsored by Novo 
Nordisk Health Care AG, Zurich, Switzerland.
Employment or leadership: M. Polak has received 
payment for his role as a member of the International 
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 29.01.19 14:16
Polak et al.: GH therapy baseline data over 10 years from NordiNet® IOS      531
Steering Committee for NordiNet® IOS. He is a member of 
the Global Norditropin® Advisory Panel (Novo Nordisk) 
and the board of the INCRELEX Registry (IPSEN). D. 
Konrad: no interests to declare. B. Tønnes Pedersen and G. 
Puras are employees of Novo Nordisk. M. Snajderova has 
received payment for her role as a member of the Interna-
tional Steering Committee for NordiNet® IOS.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
a role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; and in 
the decision to submit the report for publication.
References
1. Lee PA, Germak J, Gut R, Khutoryansky N, Ross J. Identification 
of factors associated with good response to growth hormone 
therapy in children with short stature: results from the ANSWER 
Program(R). Int J Pediatr Endocrinol 2011;2011:6.
2. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, et al. 
Derivation and validation of a mathematical model for predicting 
the response to exogenous recombinant human growth hormone 
(GH) in prepubertal children with idiopathic GH deficiency. KIGS 
International Board. Kabi Pharmacia International Growth Study. J 
Clin Endocrinol Metab 1999;84:1174–83.
3. Westphal O, Lindberg A. Final height in Swedish children 
with idiopathic growth hormone deficiency enrolled in 
KIGS treated optimally with growth hormone. Acta Paediatr 
2008;97:1698–706.
4. Ranke MB, Lindberg A, KIGS International Board. Prediction 
models for short children born small for gestational age (SGA) 
covering the total growth phase. Analyses based on data from 
KIGS (Pfizer International Growth Database). BMC Med Inform 
Decis Mak 2011;11:38.
5. Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, et al. 
Prediction of response to growth hormone treatment in short chil-
dren born small for gestational age: analysis of data from KIGS 
(Pharmacia International Growth Database). J Clin Endocrinol 
Metab 2003;88:125–31.
6. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, et al. 
Prediction of long-term response to recombinant human  
growth hormone in Turner syndrome: development and 
validation of mathematical models. KIGS International Board. 
Kabi International Growth Study. J Clin Endocrinol Metab 
2000;85:4212–8.
7. Ranke MB, Reiter E, Price D. Idiopathic growth hormone defi-
ciency in KIGS: selected aspects. In: Ranke MB, editor. Growth 
hormone therapy in pediatrics: 20 years of KIGS. Basel: Karger, 
2007:116–25.
8. Blankenstein O, Snajderova M, Blair J, Pournara E, Pedersen BT, 
et al. Real-life GH dosing patterns in children with GHD, TS or 
born SGA: a report from the NordiNet(R) International Outcome 
Study. Eur J Endocrinol 2017;177:145–55.
9. Ranke MB, Lindberg A, Tanaka T, Camacho-Hubner C, Dunger DB, 
et al. Baseline characteristics and gender differences in prepu-
bertal children treated with growth hormone in Europe,
 USA, and Japan: 25 years’ KIGS® experience (1987–2012) and 
review. Horm Res Paediatr 2017;87:30–41.
10. Hoybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, et al. 
The NordiNet® International Outcome Study and NovoNet® 
ANSWER Program®: rationale, design, and methodology of two 
international pharmacoepidemiological registry-based  studies 
monitoring long-term clinical and safety outcomes of growth 
hormone therapy (Norditropin®). Clin Epidemiol 2013;5:119–27.
11. Public Policy Committee‚ International Society of Pharmacoepi-
demiology. Guidelines for good pharmacoepidemiology practice 
(GPP). Pharmacoepidemiol Drug Saf 2016;25:2–10.
12. Cole TJ, Freeman JV, Preece MA. British 1990 growth refer-
ence centiles for weight, height, body mass index and head 
circumference fitted by maximum penalized likelihood. Stat Med 
1998;17:407–29.
13. Kobzova J, Vignerova J, Blaha P, Krejcovsky L, Riedlova J. The 6th 
nationwide anthropological survey of children and adolescents 
in the Czech Republic in 2001. Central Cent Eur J Public Health 
2004;12:126–30.
14. Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Gei HC, 
et al. Percentiles of body mass index in children and adoles-
cents evaluated from different regional German studies [Perzen-
tile für den Body-mass-Index für das Kindes- und Jugendalter 
unter Heranziehung verschiedener deutscher stichproben]. 
Monatsschrift Kinderheilkunde 2001;149:807–18.
15. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss 
children from birth to 20 years of age. First Zurich longitudinal 
study of growth and development. Helv Paediatr Acta Suppl 
1989;52:1–125.
16. Sempé M, Pédron G, Roy-Pernot MP. Auxology, methods and 
sequences [Auxologie, Méthode et Séquences]. Paris: Théraplix, 
1979.
17. Centers for Disease Control. Clinical growth charts 2000. Avail-
able from: https://www.cdc.gov/growthcharts/clinical_charts.
htm. Accessed: October 2017.
18. Novo Nordisk. Norditropin® SimpleXx® (somatropin (rDNA origin) 
for injection). Summary of Product Characteristics. Novo Nordisk 
A/S, Bagsvaerd, 2015.
19. Grimberg A, Kutikov JK, Cucchiara AJ. Sex differences in patients 
referred for evaluation of poor growth. J Pediatr 2005;146:212–6.
20. Grimberg A, Stewart E, Wajnrajch MP. Gender of pediatric recom-
binant human growth hormone recipients in the United States 
and globally. J Clin Endocrinol Metab 2008;93:2050–6.
21. Bao XL, Shi YF, Du YC, Liu R, Deng JY, et al. Prevalence of 
growth hormone deficiency of children in Beijing. Chin Med J 
1992;105:401–5.
22. Hughes IP, Choong CS, Cotterill A, Harris M, Davies PS. Gender 
bias in children receiving growth hormone treatment. J Clin 
Endocrinol Metab 2010;95:1191–8.
23. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah 
Growth Study: growth standards and the prevalence of growth 
hormone deficiency. J Pediatr 1994;125:29–35.
24. Ross J, Lee PA, Gut R, Germak J. Factors influencing the one- 
and two-year growth response in children treated with growth 
hormone: analysis from an observational study. Int J Pediatr 
Endocrinol 2010;2010:494656.
25. Polak M, Blair J, Kotnik P, Pournara E, Pedersen BT, et al. Early 
growth hormone treatment start in childhood growth hormone 
deficiency improves near adult height: analysis from NordiNet(R) 
International Outcome Study. Eur J Endocrinol 2017;177:421–9.
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 29.01.19 14:16
532      Polak et al.: GH therapy baseline data over 10 years from NordiNet® IOS
26. Darendeliler F, Lindberg A, Wilton P. Response to growth 
hormone treatment in isolated growth hormone deficiency 
versus multiple pituitary hormone deficiency. Horm Res Paediatr 
2011;76:42–6.
27. Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke 
MB. Effect of growth hormone (GH) treatment on the near-final 
height of 1258 patients with idiopathic GH deficiency: analy-
sis of a large international database. J Clin Endocrinol Metab 
2006;91:2047–54.
28. Growth Hormone Research Society. Consensus guidelines for 
the diagnosis and treatment of growth hormone (GH) deficiency 
in childhood and adolescence: summary statement of the GH 
Research Society. GH Research Society. J Clin Endocrinol Metab 
2000;85:3990–3.
29. Ranke MB, Lindberg A. Observed and predicted total pubertal 
growth during treatment with growth hormone in adolescents 
with idiopathic growth hormone deficiency, Turner syndrome, 
short stature, born small for gestational age and idiopathic 
short stature: KIGS analysis and review. Horm Res Paediatr 
2011;75:423–32.
30. Ross J, Lee PA, Gut R, Germak J. Impact of age and duration of 
growth hormone therapy in children with Turner syndrome. 
Horm Res Paediatr 2011;76:392–9.
31. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, 
et al. Recommendations for the diagnosis and management of 
Turner syndrome. J Clin Endocrinol Metab 2001;86:3061–9.
32. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, et al. 
Growth hormone treatment of early growth failure in toddlers 
with Turner syndrome: a randomized, controlled,  multicenter 
trial. J Clin Endocrinol Metab 2007;92:3406–16.
33. Spiliotis BE. Recombinant human growth hormone in 
the treatment of Turner syndrome. Ther Clin Risk Manag 
2008;4:1177–83.
34. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner 
ME, et al. Clinical practice guidelines for the care of girls and 
women with Turner syndrome: proceedings from the 2016 Cin-
cinnati International Turner Syndrome Meeting. Eur J Endocrinol 
2017;177:G1–70.
35. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapa-
port R, et al. Management of the child born small for gesta-
tional age through to adulthood: a consensus statement of 
the International Societies of Pediatric Endocrinology and the 
Growth Hormone Research Society. J Clin Endocrinol Metab 
2007;92:804–10.
36. Agence francaise de securite sanitaire des produits de sante. 
Recombinant growth hormone (recombinant somatotropin): Hor-
mone de croissance recombinante (somatropine recombinante): 
First results from the Safety and Appropriateness of GH treat-
ments in Europe (SAGhE) study [Premiers résultats de l’étude 
épidémiologique sur la tolérance à long terme (SAGhE)] 2010. 
Available from: http://ansm.sante.fr/var/ansm_site/storage/
original/application/a4d9fb2f664fd47dd331088d183c7af2.pdf. 
Accessed: October 2017.
37. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou 
F, et al. Long-term mortality after recombinant growth hormone 
treatment for isolated growth hormone deficiency or childhood 
short stature: preliminary report of the French SAGhE study. J 
Clin Endocrinol Metab 2012;97:416–25.
38. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski 
M, et al. GH safety workshop position paper: a critical appraisal 
of recombinant human GH therapy in children and adults. Eur J 
Endocrinol 2016;174:P1–9.
39. Hughes IP, Choong CS, Harris M, Ambler GR, Cutfield WS, et al. 
Growth hormone treatment for Turner syndrome in Australia 
reveals that younger age and increased dose interact to 
improve response. Clin Endocrinol (Oxf) 2011;74:473–80.
40. Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, et al. Noonan 
syndrome and Turner syndrome patients respond similarly 
to 4 years’ growth-hormone therapy: longitudinal analysis of 
growth-hormone-naive patients enrolled in the NordiNet(R) 
International Outcome Study and the ANSWER Program. Int J 
Pediatr Endocrinol 2015;2015:17.
41. Christesen HT, Pedersen BT, Pournara E, Petit IO, Juliusson 
PB. Short stature: comparison of WHO and National Growth 
 Standards/References for Height. PLoS One 2016;11:e0157277.
42. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, et al. 
Development of a WHO growth reference for school-aged chil-
dren and adolescents. Bull World Health Organ 2007;85:660–7.
43. WHO Multicentre Growth Reference Study Group. WHO Child 
Growth Standards: Length/height-for-age, weight-for-age, 
weight-for-length, weight-for-height and body mass index-for-
age: Methods and development 2006. Available from: http://
www.who.int/childgrowth/standards/technical_report/en/. 
Accessed: October 2017.
Supplemental Material: The online version of this article offers 
supplementary material (https://doi.org/10.1515/jpem-2017-0489).
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 29.01.19 14:16
